Ryan Gentzler, MD, University of Virginia, Charlottesville, VA, discusses long-term findings from the Phase II HCRN LUN13-175 trial (NCT02382406) of carboplatin, nab-paclitaxel and pembrolizumab in patients with advanced non-small cell lung cancer (NSCLC). The progression-free survival (PFS) and overall survival of patients were comparable to that of similarly designed trials such as the CheckMate 9LA (NCT03215706) and KEYNOTE-407 (NCT02775435) studies. Dr Gentzler additionally discusses racially stratified data, with people of color havening similar outcomes to other patients. This interview took place at the IASLC 2022 North America Conference on Lung Cancer (NACLC 2022).
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
